West Nile virus infection and serologic response among persons previously vaccinated against yellow fever and Japanese encephalitis viruses.
It is hypothesized that previous heterologous flaviviral exposure may modulate clinical illness among persons infected with West Nile virus (WNV). Little is known about the serological response in such persons. In summer 2003, a WNV outbreak occurred in Colorado, the location of the Centers for Disease Control and Prevention, Division of Vector-Borne Infectious Diseases (DVBID). DVBID employees, most previously vaccinated with yellow fever virus (YFV) or Japanese encephalitis virus (JEV) vaccines, were studied to determine whether previous vaccination affected symptom development among those subsequently infected with WNV during the outbreak, as well as their serological response. Serum samples collected in December 2003 and previously banked samples were tested using the plaque reduction neutralization test (PRNT) against WNV, Saint Louis encephalitis virus, dengue- 4 virus, JEV, and YFV. Specimens shown to have WNV antibody by PRNT were tested by IgM and IgG enzymelinked immunosorbent assays (ELISAs). Ten (9%) of 113 serosurvey participants had WNV neutralizing antibody titers in December 2003. PRNT titers from previous specimens showed that one of the ten had seroconverted to WNV before 2003. Of the remaining nine participants, seven reported illness in the summer of 2003, two of which were unvaccinated and five previously vaccinated. In the December 2003 specimens, five persons previously unvaccinated or vaccinated only against YFV had a fourfold or greater neutralizing titer with WNV than with other flaviviruses, whereas no persons previously vaccinated against JEV or JEV and YFV showed a similar difference in neutralizing titers. Eight of nine persons infected in 2003 had negative or indeterminate WNV MAC-ELISA results in the December 2003 sample; the ninth person was vaccinated against YFV one month previously, and was also YFV positive by MAC-ELISA. We conclude that previous flaviviral vaccination does not markedly affect the development of WNV fever and that the IgM antibody response in patients without neuroinvasive WNV disease is transient.
Johnson
B W
BW
Division of Vector-Borne Infectious Diseases (DVBID), National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado 80521, USA. bfj9@cdc.gov
Kosoy
O
O
Martin
D A
DA
Noga
A J
AJ
Russell
B J
BJ
Johnson
A A
AA
Petersen
L R
LR
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood*; D003120:Colorado / Q000453:epidemiology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D022321:Japanese Encephalitis Vaccines / Q000009:adverse effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests; D014901:West Nile Fever / Q000097:blood / Q000453:epidemiology / Q000276:immunology* / Q000473:pathology; D014902:West Nile virus / Q000276:immunology*; D022341:Yellow Fever Vaccine / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D022321:Japanese Encephalitis Vaccines; D022341:Yellow Fever Vaccine